A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia

Noriko Ohyama, Michiko Torio, Kentaro Nakashima, Yuhki Koga, Shunsuke Kanno, Hisanori Nishio, Kei Nishiyama, Momoko Sasazuki, Haru Kato, Hiroshi Asakura, Satoshi Akamine, Masafumi Sanefuji, Yoshito Ishizaki, Yasunari Sakai, Shoichi Ohga

Research output: Contribution to journalArticle

Abstract

Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.

Original languageEnglish
Article number61
JournalAnnals of Clinical Microbiology and Antimicrobials
Volume16
Issue number1
DOIs
Publication statusPublished - Sep 18 2017

Fingerprint

Toxemia
Botulism
Leukemia
Drug Therapy
Type A Botulinum Toxins
Muscle Weakness
Constipation
Progressive Bulbar Palsy
Clostridium botulinum
Mydriasis
Neoplasms
Botulinum Toxins
Globulins
Therapeutics
Bacteremia
Acute Myeloid Leukemia
Drinking
Pediatrics
Anti-Bacterial Agents
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia. / Ohyama, Noriko; Torio, Michiko; Nakashima, Kentaro; Koga, Yuhki; Kanno, Shunsuke; Nishio, Hisanori; Nishiyama, Kei; Sasazuki, Momoko; Kato, Haru; Asakura, Hiroshi; Akamine, Satoshi; Sanefuji, Masafumi; Ishizaki, Yoshito; Sakai, Yasunari; Ohga, Shoichi.

In: Annals of Clinical Microbiology and Antimicrobials, Vol. 16, No. 1, 61, 18.09.2017.

Research output: Contribution to journalArticle

Ohyama, Noriko ; Torio, Michiko ; Nakashima, Kentaro ; Koga, Yuhki ; Kanno, Shunsuke ; Nishio, Hisanori ; Nishiyama, Kei ; Sasazuki, Momoko ; Kato, Haru ; Asakura, Hiroshi ; Akamine, Satoshi ; Sanefuji, Masafumi ; Ishizaki, Yoshito ; Sakai, Yasunari ; Ohga, Shoichi. / A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia. In: Annals of Clinical Microbiology and Antimicrobials. 2017 ; Vol. 16, No. 1.
@article{53baac28436047028760a67d779f73ff,
title = "A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia",
abstract = "Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.",
author = "Noriko Ohyama and Michiko Torio and Kentaro Nakashima and Yuhki Koga and Shunsuke Kanno and Hisanori Nishio and Kei Nishiyama and Momoko Sasazuki and Haru Kato and Hiroshi Asakura and Satoshi Akamine and Masafumi Sanefuji and Yoshito Ishizaki and Yasunari Sakai and Shoichi Ohga",
year = "2017",
month = "9",
day = "18",
doi = "10.1186/s12941-017-0240-y",
language = "English",
volume = "16",
journal = "Annals of Clinical Microbiology and Antimicrobials",
issn = "1476-0711",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A childhood-onset intestinal toxemia botulism during chemotherapy for relapsed acute leukemia

AU - Ohyama, Noriko

AU - Torio, Michiko

AU - Nakashima, Kentaro

AU - Koga, Yuhki

AU - Kanno, Shunsuke

AU - Nishio, Hisanori

AU - Nishiyama, Kei

AU - Sasazuki, Momoko

AU - Kato, Haru

AU - Asakura, Hiroshi

AU - Akamine, Satoshi

AU - Sanefuji, Masafumi

AU - Ishizaki, Yoshito

AU - Sakai, Yasunari

AU - Ohga, Shoichi

PY - 2017/9/18

Y1 - 2017/9/18

N2 - Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.

AB - Background: Botulism is a potentially fatal infection characterized by progressive muscle weakness, bulbar paralysis, constipation and other autonomic dysfunctions. A recent report suggested that cancer chemotherapy might increase the risk for the intestinal toxemia botulism in both adults and children. Case presentation: We report a 5-year-old boy, who developed general muscle weakness, constipation, ptosis and mydriasis during the third induction therapy for relapsed acute myeloid leukemia. He had recent histories of multiple antibiotic therapy for bacteremia and intake of well water at home. Repeated bacterial cultures identified Clostridium botulinum producing botulinum neurotoxin A. Botulinum toxin A was isolated from his stools at 17, 21, and 23 days after the onset. Symptoms were self-limiting, and were fully recovered without anti-botulinum toxin globulin therapy. Conclusion: This is the second report of a pediatric case with cancer chemotherapy-associated intestinal toxemia botulism. Our case provides further evidence that the immunocompromised status due to anti-cancer treatments increases the risk for the development of botulism at all ages in childhood.

UR - http://www.scopus.com/inward/record.url?scp=85029608022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029608022&partnerID=8YFLogxK

U2 - 10.1186/s12941-017-0240-y

DO - 10.1186/s12941-017-0240-y

M3 - Article

C2 - 28923072

AN - SCOPUS:85029608022

VL - 16

JO - Annals of Clinical Microbiology and Antimicrobials

JF - Annals of Clinical Microbiology and Antimicrobials

SN - 1476-0711

IS - 1

M1 - 61

ER -